SR One Capital Management LP acquired a new stake in Alumis Inc. (NASDAQ:ALMS - Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 1,959,896 shares of the company's stock, valued at approximately $26,067,000. Alumis makes up about 8.2% of SR One Capital Management LP's holdings, making the stock its 4th largest holding. SR One Capital Management LP owned about 4.20% of Alumis as of its most recent filing with the Securities & Exchange Commission.
Separately, Towerview LLC bought a new stake in Alumis during the second quarter worth $4,123,000.
Alumis Stock Performance
NASDAQ:ALMS traded up $0.10 on Friday, hitting $11.47. The stock had a trading volume of 2,712,844 shares, compared to its average volume of 189,575. Alumis Inc. has a 1 year low of $10.37 and a 1 year high of $13.53. The firm's fifty day simple moving average is $12.24.
Alumis (NASDAQ:ALMS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($23.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.57) by ($21.53). As a group, sell-side analysts forecast that Alumis Inc. will post -6.86 earnings per share for the current year.
Analysts Set New Price Targets
ALMS has been the topic of several recent analyst reports. Guggenheim started coverage on Alumis in a research note on Tuesday, July 23rd. They set a "buy" rating and a $32.00 price objective on the stock. Leerink Partnrs upgraded shares of Alumis to a "strong-buy" rating in a report on Tuesday, July 23rd. Morgan Stanley assumed coverage on shares of Alumis in a research report on Tuesday, July 23rd. They issued an "overweight" rating and a $36.00 price objective for the company. Leerink Partners assumed coverage on shares of Alumis in a research note on Tuesday, July 23rd. They issued an "outperform" rating and a $29.00 price objective for the company. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Alumis in a research note on Monday, August 19th. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $27.50.
View Our Latest Report on Alumis
About Alumis
(
Free Report)
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Featured Articles
Before you consider Alumis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alumis wasn't on the list.
While Alumis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
